Roundhill GLP-1 & Weight Loss ETF
Key Statistics
Historical Performance
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
Top 25 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →
About OZEM
The Fund is an actively managedexchange-traded fund (“ETF”) that pursues its investment objective by seeking to provide exposure to companies involved inthe development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight,and/or maintain body composition during weight loss (“GLP-1 & Weight Loss Drugs”). The Fund will focus its investmentsin the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it definesas those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food &Drug Administration (“FDA”) clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have beenapproved by the FDA (“GLP-1 & Weight Loss Companies”). For non-U.S. companies that are not subject to oversight by theFDA, the Fund may classify such company as a GLP-1 & Weight Loss Company if that company’s GLP-1 & Weight Loss Drug is currentlyundergoing clinical trials subject to regulatory oversight by that company’s applicable food and drug regulator or if that company’sGLP-1 & Weight Loss Drug has been approved by the company’s applicable food and drug regulator. The Fund will invest at least80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies. In seeking to achieve the Fund’sinvestment objective, the Fund’s investment adviser, Roundhill Financial Inc. (“Roundhill” or the “Adviser”),constructs the Fund’s portfolio pursuant to its own proprietary security selection methodology. In general, the methodology prioritizescompanies with higher levels of “thematic relevance,” which is based upon research on individual companies’ public disclosures(e.g., 10-K filings, company presentations, capital markets day presentations, etc.) and other publicly available sources (e.g.,sell-side research, biotechnology industry publications, drug development pipeline trackers, etc.). The Fund will also only invest inthose companies with a minimum market capitalization of $100 million and an average daily trading volume of $500,000. The Adviser rebalancesthe weighting of the companies comprising the Fund’s portfolio on at least a quarterly basis. The Fund may invest in U.S. and non-U.S.companies (including those operating in developed or emerging market countries) through investments in depositary receipts, American DepositaryReceipts (“ADRs”) or Global Depositary Receipts (“GDRs”), including depositary receipts whose underlying securitiesare non-voting preferred securities. Such companies will be small-, mid- and large-capitalization issuers. The Fund will concentrate (i.e.,invest more than 25% of its total assets) its investments in the industry or group of industries comprising the health care sector. Asof March 31, 2026, the Fund had significant investments in European companies. To the extent the Fund invests a significant portion ofits assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investmentsector. The Fund is classified as “non-diversified”under the Investment Company Act of 1940 (the “1940 Act”).
OZEM News
- Trading the Move, Not the Narrative: (OZEM) Edition
- The Technical Signals Behind (OZEM) That Institutions Follow
- Precision Trading with Roundhill Etf Trust Glp-1 & Weight Loss Etf (OZEM) Risk Zones
- Technical Reactions to OZEM Trends in Macro Strategies
- Technical Reactions to OZEM Trends in Macro Strategies
- Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%
- Trading the Move, Not the Narrative: (OZEM) Edition
- Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
- Oak Family Advisors LLC Sells 29,464 Shares of Roundhill GLP-1 & Weight Loss ETF $OZEM
- (OZEM) Volatility Zones as Tactical Triggers
- Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Data for OZEM is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.